Showing 15 posts of 24 posts found.

ImmuPharma initiates phase 2/3 clinical trial for lupus treatment

June 19, 2023
Research and Development Avion Pharmaceuticals, ImmuPharma, Immunology, Lupus, clinical trial

ImmuPharma has announced that it will commence a phase 2/3 adaptive clinical trial of P140 (Lupuzor) in patients with systemic …

GSK building

GSK lupus treatment approved by European Commission

May 6, 2021
GSK, Lupus, lupus treatment, pharma, pharma news

GSK’s Benlysta treatment, for patients with active lupus nephritis (LN) in addition to systemic lupus erythematosus (SLE), has been approved …


Immupharma and Avion sign agreement for lupus drug Lupuzor

November 29, 2019
Medical Communications Diseases, Lupus, Lupuzor, avion

Immupharma has signed a development agreement with Avion Pharmaceuticals to acquire the licensing rights for Lupuzor, a peptide therapeutic and …

Expanded EU label for Benlyta now covers paediatric lupus patients

October 30, 2019
Research and Development, Sales and Marketing Benlyta, Europe, GSK, Lupus, pharma

GlaxoSmithKline is celebrating the news that the European Commission has chosen to approve an expansion to the label of its …


Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome

October 28, 2019
Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma

Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …


AstraZeneca lupus drug makes comeback to meet main goal at Phase 3

August 29, 2019
Research and Development AstraZeneca, Lupus, anifrolumab, pharma

AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint …


GSK’s Benlysta becomes first FDA-approved IV therapy for paediatric lupus

April 30, 2019
Manufacturing and Production, Sales and Marketing Benlysta, FDA, GSK, Lupus, US, pharma

GSK has scored approval in the US with Benlysta (belimumab) for the treatment of systemic lupus erythematosus (SLE) in paediatric …


UCB and Biogen’s lupus drug falls short at Phase 2b

October 24, 2018
Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure

The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …


AZ’s lupus drug fails to curb lupus activity at Phase 3

August 31, 2018
Medical Communications, Research and Development AstraZeneca, Lupus, anifrolumab, pharma

AstraZeneca and its biologics R&D arm MedImmune have released a statement admitting that their fully human monoclonal antibody anifrolumab failed …


Interview: GSK’s subcutaneous formulation for Benlysta may help cut down hospital visits

June 22, 2016
Research and Development Benlysta, EULAR, Interview, Lupus, NICE, autoimmune diseases, drug trial

UK drugmaker GlaxoSmithKine (LSE: GSK) reported positive results for Benlysta following a late-stage study at the annual European Congress of …


GSK ready for lupus drug push

November 12, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Benlysta, GSK, Lupus, SLE, belimumab, systemic lupus erythematosus

Having presented positive late-stage results for a new formulation of its inflammatory drug Benlysta, GSK says it will file supplementary …

Astrazeneca image

AstraZeneca partners with PatientsLikeMe

April 14, 2015
Sales and Marketing AstraZeneca, Lupus, PatientsLikeMe, Roche, diabetes, oncology, respiratory disease

AstraZeneca has signed a five-year agreement with PatientsLikeMe to give the pharma firm access to the latter’s global network of …

Merck Serono image

Research pact joins Pfizer and Merck Serono with academics

April 3, 2014
Research and Development, Sales and Marketing Lupus, Merck Serono, Pfizer, broad institute, emd, kidney

Merck’s US affiliate EMD Serono and Pfizer have entered into a research agreement with the Broad Institute to investigate autoimmune …

Pfizer signs drug profiling deal with Nodality

August 10, 2012
Research and Development, Sales and Marketing Lupus, Nodality, Pfizer, SCNP

Pfizer has signed a multi-year drug profiling deal with Nodality to help get the best from its autoimmune disease compounds. …

Benlysta image

NICE no to GSK’s lupus drug Benlysta

April 27, 2012
Sales and Marketing Andrew Dillon, Benlysta, GSK, Lupus, NICE

NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly.  In its final …

Latest content